Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Shore

Showing results (51-60 of 191) with videos related to

Pageof 20
Sort By:
European Urology|October 13, 2023
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyBertrand Tombal, Sean Collins, Alicia K Morgans, et al.
The Journal of Urology|August 1, 2024
Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)Neal Shore, Jason Hafron, Daniel Saltzstein, et al.
International Journal of Clinical Oncology|June 25, 2026
Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancerNeal Shore, Nguyen, Barinder Kang, et al.
Journal of Cancer|September 14, 2017
A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on BiopsyMaher Albitar, Wanlong Ma, Lars Lund, et al.
BJU International|April 11, 2012
Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) surveyMatthew E Nielsen, Angela B Smith, Raj S Pruthi, et al.
The Prostate|January 10, 2018
Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancerMaher Albitar, Wanlong Ma, Lars Lund, et al.
JAMA Oncology|October 17, 2018
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review, Christopher Parker, Valerie Lewington, et al.
European Urology|January 21, 2014
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonistsLaurence Klotz, Kurt Miller, E David Crawford, et al.
Advances in Cancer Research|September 21, 2024
Advances in prostate cancer treatment: Radionuclide therapy for prostate cancerJeffrey Zhong, Albert Jang, Jorge Garcia, et al.
The Journal of Urology|December 17, 2020
Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene AlterationsNeal Shore, Louisa Oliver, Irene Shui, et al.
Pageof 20

Showing results (51-60 of 191) with videos related to

Sort By:
Pageof 20
European Urology|October 13, 2023
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO StudyBertrand Tombal, Sean Collins, Alicia K Morgans, et al.
The Journal of Urology|August 1, 2024
Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)Neal Shore, Jason Hafron, Daniel Saltzstein, et al.
International Journal of Clinical Oncology|June 25, 2026
Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancerNeal Shore, Nguyen, Barinder Kang, et al.
Journal of Cancer|September 14, 2017
A Multi-Center Prospective Study to Validate an Algorithm Using Urine and Plasma Biomarkers for Predicting Gleason ≥3+4 Prostate Cancer on BiopsyMaher Albitar, Wanlong Ma, Lars Lund, et al.
BJU International|April 11, 2012
Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) surveyMatthew E Nielsen, Angela B Smith, Raj S Pruthi, et al.
The Prostate|January 10, 2018
Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancerMaher Albitar, Wanlong Ma, Lars Lund, et al.
JAMA Oncology|October 17, 2018
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review, Christopher Parker, Valerie Lewington, et al.
European Urology|January 21, 2014
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonistsLaurence Klotz, Kurt Miller, E David Crawford, et al.
Advances in Cancer Research|September 21, 2024
Advances in prostate cancer treatment: Radionuclide therapy for prostate cancerJeffrey Zhong, Albert Jang, Jorge Garcia, et al.
The Journal of Urology|December 17, 2020
Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene AlterationsNeal Shore, Louisa Oliver, Irene Shui, et al.
Pageof 20